Giancarlo Moscol, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor (Joint appointment), Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, General Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Breast Medical Oncology-Rsch, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, General Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Clinical Assistant Professor, Hematology/Oncology, UTMB, Galveston, TX
Education & Training
Degree-Granting Education
| 2006 | San Marcos University, San Fernando School of Medicine, Lima, PE, MD |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Hematology and Medical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas |
| 2009-2012 | Clinical Residency, Internal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania |
Licenses & Certifications
| 2023 | Florida Board of Medicine |
| 2017 | DEA |
| 2017 | Hematology and Medical Oncology |
| 2014 | Texas State Board License |
| 2012 | American Board of Internal Medicine |
| 2009 | BLS Certification |
Experience & Service
Administrative Appointments/Responsibilities
Leader, Breast Medical Oncology, MDACC Breast Medical Oncology Tumor Board, The Woodlands, TX, 2018 - Present
Other Professional Positions
Clinical Instructor, Thomas Jefferson University Hospital, Bone Marrow Transplant Unit, Department of Medical Oncology, Philadelphia, PA, 2012 - 2014
Chief Resident, Clinica El Golf Medical Center, Lima, 2007 - 2009
Attending Physician, Santa Rosa Military Hospital, Iquitos, 2006 - 2007
Practice Coordinator, San Marcos University, San Fernando School of Medicine, Lima, 2002 - 2004
Extramural Institutional Committee Activities
Member, IRB, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, MDACC Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2023 - 2026
Leader and Breast Medical Oncology Liaison, Project ECHO (Extension for Community Healthcare Outcomes), The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, HALs Research Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, St. Luke's-MDACC Multidisciplinary Tumor Board, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Breast Medical Oncology Multidisciplinary Tumor Board, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, American Society of Clinical Oncology Technology Research Group, American Society of Clinical Oncology Technology Research Group, 2017 - Present
Editorial Activities
Invited manuscript reviewer for original article submission, BMC cancer, 2024 - Present
Invited manuscript reviewer for Her2 positive metastatic breast cancer, Cureus, 2023 - Present
Invited manuscript reviewer for original article in TNBC, Breast cancer research and treatment, 2023 - Present
Invited manuscript reviewer for original articles, Journal of Clinical Global Oncology, 2022 - Present
Honors & Awards
| 2023 | Top 1% Patient Satisfaction Scores Awardee, MD Anderson Cancer Center |
| 2021 - 2022 | Top 1% Patient Satisfaction Scores Awardee, MD Anderson Cancer Center |
| 2015 | Best Fellow's Research Award, Texas Society of Clinical Oncology Annual Meeting, Austin, Texas |
| 2005 | Best Intern of the Year, Arzobispo Loayza National Hospital, Lima Peru |
| 2003 - 2005 | Scholarship Award for Excellence in Academic Performance, Hipolito Unanue Medical Society |
| 2002 - 2006 | Dean's List, University of San Marcos |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Her2 metastatic breast cancer: standing in the shoulder of giants. Invited. Stefanie Spielman Conference Series. Columbus, Ohio, US.
- 2024. Triple Negative Breast Cancer: new targets for an old disease. Invited. Mc Govern Medical School Oncology Grand Rounds. Houston, Texas, US.
- 2024. Breast cancer: learn how to reduce your risk. Invited. EDAYE Hope & Love Foundation. La Porte, Texas, US.
- 2023. Breast Cancer Survivorship. Invited. Canopy The Woodlands. The Woodlands, Texas, US.
Regional Presentations
- 2025. Updates in Management of Advanced Her2 Positive Breast Cancer. Invited. 2025 Breast Cancer Symposium. Houston, Texas, US.
International Presentations
- 2025. Updates in TNBC: New targets for an old disease. Invited. Grand Rounds - GUS Medical School. Grand Cayman, KY.
- 2022. Guest Lecturer. Invited. Guadalajara, MX.
- 2020. Guest Lecturer. Invited. Lima, PE.
Formal Peers
- 2025. Updates in HER2+ ABC Therapeutics. Houston, TX, US.
- 2024. Primer in Breast Medical Oncology. Lima, PE.
- 2024. Use of antibody drug conjugates in TNBC. Houston, Texas, US.
- 2024. Triple Negative Breast Cancer: new targets for an old disease. Houston, TX, US.
- 2023. Breast Cancer Survivorship and Follow Up Care. Invited. The Woodlands, TX, US.
- 2023. Optimizing Breast Cancer screening for the general population. Invited. Huntsville, TX, US.
- 2023. Newer Antibody Drug Conjugates for treatment of Breast Cancer. Invited. Louisville, KY, US.
- 2023. Introduction to medical oncology: a primer for college students. Invited. Conroe, TX, US.
- 2022. Primer on Breast Medical Oncology: what all medical students should know. Invited. Guadalajara, Jalisco, MX.
- 2022. Update on Breast Cancer: Personalizing Diagnosis and Treatment. Invited. Houston, TX, US.
- 2020. Immunotherapy: Primer in Immunotherapy for Medical Oncologists. Invited. Lima, PE.
- 2020. Triple Negative Breast Cancer: immunotherapy and beyond. Invited. Lima, PE.
Selected Publications
Peer-Reviewed Articles
- Julca Marin, DI, Chávez Paredes, G, Alegre, I, Rudas Sulca, BE, Montes, A, Baltazar Ñahui, HK, Lopez Luza, A, Guerra, O, Quispe, C, Moscol, G. The HALP Score as a Prognostic Biomarker in Non-small Cell Lung Cancer. Journal of Clinical Oncology 43:e20031-e20031, 2025. e-Pub 2025.
- Valga, F, Monzon, T, Vega-Diaz, N, Santana, A, Moscol, G, Ruiz-Santana, S, Rodriguez-Perez, JC. Serum Chloride as a Marker of Cardiovascular and All-cause Mortality in Chronic Hemodialysis Patients. Nefrologia 43:47-56, 2023. e-Pub 2023.
Abstracts
- Yam C, Radko A, Huo L, Akshara S, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas CH, Bisen A, Brewster A, Buzdar A, Gregor M, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme AN, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward W, Hunt K, Litton J, Valero V, Tripathy D, Rauch GM, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Wright MD, Yam C, Iwase T, Nelson B, Bassett R, Singareeka A, Whitman G, Karuturi M, Adrada B, Kizub D, Guirguis M, Buzdar A, Moseley T, Nwosu-Iheme A, Kapoor M, Sukumar J, Thomas P, Barcenas CH, Ibrahim N, Moscol G, Nasrazadani A, Ramirez D, Lee J, Woodward WA, Litton JK, Hunt K, Giordano S, Tripathy D, Valero V, Huo L, Rauch GM, Ueno N. Neosaci-io: Neoadjuvant Sacituzumab Govitecan (sg) + Pembrolizumab (pb) in Patients (pts) with Early-stage TNBC Experiencing Suboptimal Response to Keynote-522. Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Mouabbi JA, Raghavendra A, Pasyar S, Roland B, Mukhtar R, Moscol G, Wright MD, Bisen AK, Iheme AN, Barcenas CH, Valero V, Nasrazadani A, Lim B, Ramirez DL, Hassan A, Kuerer H, Adesoye T, Paula P, Meric-Bernstam F, Giordano SH, Litton JK, Layman RM. Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). Clin Cancer Res 32(4 Supplement), 2026. e-Pub 2026.
- Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, M Rauch AG. Early-on Treatment (on-Rx) Tumor Volume Reduction (TVR) to Predict Response to the KEYNOTE-522 (KN-522) Regimen in Early Stage Triple Negative Breast Cancer (TNBC). J Clin Oncol 43(16 Supplemental:592), 2025. e-Pub 2025.
Book Chapters
- Moscol, G, Mitchell, MP, Hwang, RF. Breast Cancer, 227-257, 2024.
- Moscol G, Mitchell M, Teshome M. Breast Cancer. In: Gynecologic Care of the Female Cancer Patient. Cambridge Press.
Patient Reviews
CV information above last modified July 22, 2026